Chemotherapy vs. allogeneic transplantation as post molecular remission therapy in patients aged less than 60 years with Philadelphia-positive ALL

Bone Marrow Transplant. 2020 Jan;55(1):245-248. doi: 10.1038/s41409-019-0514-4. Epub 2019 Mar 27.

Authors

Libing Wang^#¹, Juan Du^#², Aijie Huang^#¹, Gusheng Tang¹, Shenglan Gong¹, Hui Cheng¹, Weiping Zhang¹, Jianmin Yang¹, Jianmin Wang¹, Xiaoxia Hu³

Affiliations

¹ Department of Hematology, Institute of Hematology, Changhai Hospital, 200433, Shanghai, China.
² Department of Hematology, Changzheng Hospital, 200003, Shanghai, China.
³ Department of Hematology, Institute of Hematology, Changhai Hospital, 200433, Shanghai, China. hu_xiaoxia@126.com.

^# Contributed equally.

PMID: 30918339
DOI: 10.1038/s41409-019-0514-4

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Hematopoietic Stem Cell Transplantation*
Humans
Remission Induction
Transplantation, Homologous